Comparative Pharmacology
Head-to-head clinical analysis: ELCYS versus L GLUTAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELCYS versus L GLUTAMINE.
ELCYS vs L-GLUTAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELCYS (eltrombopag olamine) is a small molecule agonist of the thrombopoietin receptor (TPO-R) on hematopoietic stem cells and megakaryocytes, activating JAK-STAT signaling to stimulate megakaryopoiesis and platelet production.
L-glutamine is a conditionally essential amino acid that serves as a precursor for nucleotide synthesis, glutathione production, and energy metabolism. It modulates heat shock protein expression, supports intestinal epithelial cell proliferation, and attenuates glutamine metabolism in cancer cells, particularly in hematologic malignancies.
100 mg orally three times daily
Oral: 10-15 g three times daily (30-45 g/day). Powder dissolved in beverage. For sickle cell disease: 0.3 g/kg twice daily (max 30 g/day).
None Documented
None Documented
Clinical Note
moderateL-Glutamine + Lactulose
"The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine."
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Terminal half-life approximately 1.5-2 hours in adults; clinically, enteral supplementation requires frequent dosing to maintain plasma levels.
Primarily renal (approx. 35-50% unchanged drug) and biliary/fecal (about 50-60% as metabolites).
Renal: ~5-10% unchanged; biliary/fecal: negligible; majority metabolized by enterocytes and liver to glutamate, ammonia, and other amino acids.
Category C
Category C
Amino Acid Supplement
Amino Acid Supplement